(Q37641754)

21 August 2017

1 reference

title

Clinical implications of mucosal healing for the management of IBD. (English)

1 reference

21 August 2017

Laurent Peyrin-Biroulet

series ordinal

2

object named as

Laurent Peyrin-Biroulet

1 reference

21 August 2017

Jean-Frédéric Colombel

series ordinal

4

object named as

Jean-Frédéric Colombel

1 reference

21 August 2017

3

Marc Lémann

1 reference

Guillaume Pineton de Chambrun

21 August 2017

series ordinal

1

object named as

Guillaume Pineton de Chambrun

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Nature Reviews Gastroenterology & Hepatology

21 August 2017

1 reference

21 August 2017

7

1 reference

21 August 2017

1

1 reference

21 August 2017

15-29

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2009.203

21 August 2017

0 references

cites work

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A protective role of protease-activated receptor 1 in rat gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Current directions in IBD therapy: what goals are feasible with biological modifiers?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Disease activity courses in a regional cohort of Crohn's disease patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Endoscopic healing should be a goal for everyone with ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Importance of mucosal healing in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Review article: Crohn's disease: monitoring disease activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Cortisone in ulcerative colitis; final report on a therapeutic trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A Comparison of Oral Prednisolone Given as Single or Multiple Daily Doses for Active Proctocolitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Cortisone in ulcerative colitis; preliminary report on a therapeutic trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Intensive intravenous regimen for severe attacks of ulcerative colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Methotrexate for the Treatment of Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Does methotrexate induce mucosal healing in Crohn's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Infliximab for induction and maintenance therapy for ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Enteral nutrition for maintenance of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Polymeric Diet Alone Versus Corticosteroids in the Treatment of Active Pediatric Crohn’s Disease: A Randomized Controlled Open-Label Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Enteral nutritional therapy for induction of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Microscopic activity in ulcerative colitis: what does it mean?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Long-term outcome after infliximab for refractory ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Nuclear factor-kappaB in cancer development and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Review article: can post-operative recurrence in Crohn's disease be prevented?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Review article: recurrence of Crohn's disease after surgery - the need for treatment of new lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.203

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

31 March 2020

1 reference

12 December 2020

Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy

1 reference

12 December 2020

Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.

1 reference

12 December 2020

Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

1 reference

12 December 2020

Influence of treatment on morphological features of mucosal inflammation

1 reference

12 December 2020

Predictability of the postoperative course of Crohn's disease

1 reference

12 December 2020

Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania

1 reference

12 December 2020

10.1038/NRGASTRO.2009.203

Identifiers

DOI

1 reference

21 August 2017

1 reference